摘要

Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis. Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status. Conclusion and Clinical Relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways.
原文英語
期刊Proteomics - Clinical Applications
DOIs
出版狀態接受/付印 - 一月 1 2018

指紋

Pemetrexed
Chemotherapy
Non-Small Cell Lung Carcinoma
Proteomics
Cisplatin
T-cells
Cells
Membranes
Drug Therapy
Proteome
Blood
CTLA-4 Antigen
Immune system
Cell membranes
Disease-Free Survival
T-Cell Antigen Receptor
Blood Cells
Neutrophils
T-Lymphocytes
Antigens

Keywords

  • non-small-cell lung cancer
  • peripheral blood mononuclear cells
  • personalized membrane proteomics

ASJC Scopus subject areas

  • Clinical Biochemistry

引用此文

Chemotherapy Immunophenoprofiles in Non-Small-Cell Lung Cancer by Personalized Membrane Proteomics. / Putri, Denise Utami; Feng, Po Hao; Hsu, Yuu Hueih; Lee, Kang Yun; Jiang, Feng Wen; Kuo, Lu Wei; Chen, Yu Ju; Han, Chia Li.

於: Proteomics - Clinical Applications, 01.01.2018.

研究成果: 雜誌貢獻文章

@article{25dcae327fa549e2b9794f057d7a46f7,
title = "Chemotherapy Immunophenoprofiles in Non-Small-Cell Lung Cancer by Personalized Membrane Proteomics",
abstract = "Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis. Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status. Conclusion and Clinical Relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways.",
keywords = "Non-small-cell lung cancer, Peripheral blood mononuclear cells, Personalized membrane proteomics, non-small-cell lung cancer, peripheral blood mononuclear cells, personalized membrane proteomics",
author = "Putri, {Denise Utami} and Feng, {Po Hao} and Hsu, {Yuu Hueih} and Lee, {Kang Yun} and Jiang, {Feng Wen} and Kuo, {Lu Wei} and Chen, {Yu Ju} and Han, {Chia Li}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/prca.201700040",
language = "English",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",

}

TY - JOUR

T1 - Chemotherapy Immunophenoprofiles in Non-Small-Cell Lung Cancer by Personalized Membrane Proteomics

AU - Putri, Denise Utami

AU - Feng, Po Hao

AU - Hsu, Yuu Hueih

AU - Lee, Kang Yun

AU - Jiang, Feng Wen

AU - Kuo, Lu Wei

AU - Chen, Yu Ju

AU - Han, Chia Li

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis. Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status. Conclusion and Clinical Relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways.

AB - Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis. Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status. Conclusion and Clinical Relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways.

KW - Non-small-cell lung cancer

KW - Peripheral blood mononuclear cells

KW - Personalized membrane proteomics

KW - non-small-cell lung cancer

KW - peripheral blood mononuclear cells

KW - personalized membrane proteomics

UR - http://www.scopus.com/inward/record.url?scp=85040739471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040739471&partnerID=8YFLogxK

U2 - 10.1002/prca.201700040

DO - 10.1002/prca.201700040

M3 - Article

AN - SCOPUS:85040739471

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

ER -